Brazil’s Federal Court Reviews Medicines Mailbox Patents
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...
The last mile: A few suggestions for the WHO Pandemic Agreement’s last two weeks...
This technical briefing note is also available as a PDF here.
On 16 April, the Bureau of the Intergovernmental Negotiating Body (INB) to draft and...
How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the...
Patents usually confer 20-year exclusive rights on inventions. Data exclusivity laws confer, depending on the country, 5 to 10 years’ exclusive rights over safety...
Continuing to ignore the problem of the know-how gap won’t make it go away.
The Covid-19 pandemic was a wake-up call for a variety of issues in access to medicines, one of which was finding a solution to...
Submission to the US International Trade Commission
On 17 June 2022, World Trade Organization (WTO) Members adopted a Ministerial Decision outlining flexibilities in the WTO’s Trade Related Aspects of Intellectual Property...
EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade...
Negotiations are currently taking place at the World Health Organization (WHO) to conclude a new pandemic agreement by May 2024. The objective of the...
The European Commission says Covid-19 vaccines should be global public goods, but do their...
The European Commission has entered into advance purchase agreements (APAs) for Covid-19 vaccines with six pharmaceutical companies and is concluding negotiations with two companies....
European Parliament’s amendments make the Regulation for EU-wide compulsory licensing difficult to use and...
European Parliament legislative resolution of 13 March 2024, on the proposal for a regulation of the European Parliament and of the Council on compulsory...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...